Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 0.43 — trading below book value
- Piotroski F-Score 6/9 — moderate financial health
- Loss-making — negative ROE of -1.0%
- High dividend yield of 12.3%
Perrigo Company plc (PRGO) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $1.3 billion . Key value metrics: P/B ratio 0.43, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Perrigo Company plc — Fundamental Analysis Summary
On financial health, PRGO shows a moderate Piotroski F-Score of 6/9, and negative return on equity of -1.0% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.24.
StockPik's composite Value Score for PRGO is 77/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PRGO reports a moderate gross margin of 36.3% (sector average: 33.5%) and a modest operating margin of 5.8%.
PRGO shows revenue declining at 3% year-over-year, with earnings declining at 730%.
PRGO pays a high dividend yield of 12.3%.